Adipokines and adipocytokines in men with coronary atherosclerosis and overweight

Aim    To study concentrations of adipokines and their associations with proinflammatory cytokines in overweight men with coronary atherosclerosis. 
Material and methods    This study included 79 men aged 45–60 years with atherosclerosis who had undergone coronary endarterectomy during a coronary bypass surgery, and were overweight (body weight index (BWI), 25.0–29.9 kg /m2). Based on a histological analysis of plaques, the patients were divided into two subgroups: 43 men with stable atherosclerotic plaques and 36 men with unstable plaques in coronary arteries. The control group consisted of 40 age- and BWI-matched men without clinical manifestations of IHD. Blood concentrations of adipokines, including adiponectin, adipsin, lipocalin-2, resistin, and plasminogen 1 activator inhibitor were measured by a multiplex analysis with a MILLIPLEX MAP Human Adipokine Panel 1. Concentrations of proinflammatory cytokines, including tumor necrosis factor α (TNF- α), interleukin (IL)-1β, IL-6, and C-reactive protein (CRP) were measured by enzyme immunoassay. 
Results    The blood concentration of lipocalin -2 was higher in patients with coronary atherosclerosis and stable or unstable atherosclerotic plaques than in the control group (p<0.01). Both subgroups of men with coronary atherosclerosis were characterized by significant differences from the control group in concentrations of TNF-α (p<0.05), CRP, and IL-6 (p<0.01). The most significant direct correlations were found between adipokines and TNF-α, IL-6, and CRP (p<0.01). Results of a logistic regression analysis showed that relative odds for the presence of significant coronary stenoses increased with increasing blood concentrations of lipocalin-2 (OR=1.005, 95 % CI: 1.002–1.008, р=0.011) and IL-6 (OR=1.582 , 95 % CI: 1.241–2.017, р=0.001).
Conclusion    The changes in blood concentrations of adipokines associated with higher levels of proinflammatory cytokines may represent a factor that increases the probability of clinically significant coronary stenosis in overweight men with coronary atherosclerosis.

1. Chaulin A.M., Grigorieva Yu.V., Duplyakov D.V. Modern ideas about the pathophysiology of atherosclerosis. Part 1. The role of lipid metabolism disorders and endothelial dysfunction (literature review). Medicine in Kuzbass. 2020;19(2):34–41. DOI: 10.24411/2687-0053-2020-10015

2. Soylu K, Aksan G, Nar G, Ozdemir M, Gulel O, Inci S et al. Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome. The Anatolian Journal of Cardiology. 2015;15(16):450–5. DOI: 10.5152/akd.2014.5513

3. Akhmedov V.A., Shevchenko A.S., Isaeva A.S. Current view on the atherosclerosis emergence and progression factors. Russian Medical Journal. Medical Review. 2019;1(II):57–62.

4. Ikonomidis I, Michalakeas CA, Parissis J, Paraskevaidis I, Ntai K, Papadakis I et al. Inflammatory markers in coronary artery disease. Bio-Factors. 2012;38(5):320–8. DOI: 10.1002/biof.1024

5. Martinez E, Martorell J, Riambau V. Review of serum biomarkers in carotid atherosclerosis. Journal of Vascular Surgery. 2020;71(1):329–41. DOI: 10.1016/j.jvs.2019.04.488

6. Nakamura K, Fuster JJ, Walsh K. Adipokines: A link between obesity and cardiovascular disease. Journal of Cardiology. 2014;63(4):250– 9. DOI: 10.1016/j.jjcc.2013.11.006

7. Van de Voorde J, Pauwels B, Boydens C, Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62(11):1513–21. DOI: 10.1016/j.metabol.2013.06.004

8. Ragino Yu.I., Shcherbakova L.V., Oblaukhova V.I., Polonskaya Ya.V., Stakhneva E.M., Kuzminykh N.A. et al. Blood Adipokins in Young People with Early Ischemic Heart Disease on the Background of Abdominal Obesity. Kardiologiia. 2021;61(4):32–8. DOI: 10.18087/cardio.2021.4.n1369

9. Qasim A, Mehta NN, Tadesse MG, Wolfe ML, Rhodes T, Girman C et al. Adipokines, Insulin Resistance, and Coronary Artery Calcification. Journal of the American College of Cardiology. 2008;52(3):231–6. DOI: 10.1016/j.jacc.2008.04.016

10. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR et al. Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2004;89(8):3872–8. DOI: 10.1210/jc.2003-031676

11. Martin SS, Qasim AN, Rader DJ, Reilly MP. C-Reactive Protein Modifies the Association of Plasma Leptin With Coronary Calcium in Asymptomatic Overweight Individuals. Obesity. 2012;20(4):856–61. DOI: 10.1038/oby.2011.164

12. Jover E, Hernandez-Romero D, Hurtado JA, Romero-Aniorte AI, Casas T, Valdes M. Serum adiponectin level as a biomarker of coronary artery calcification and severe coronary lesions. Revista Espanola de Cardiologia. 2012;65(11):1060–1. DOI: 10.1016/j.recesp.2012.03.031

13. Miller SW, Boxt LM, Abbara S. Cardiac Imaging: The Requisites EBook. 3rd ed. -Elsevier Health Sciences: Mosby;2009. - 456 p. ISBN 978-0-323-07674-6

14. Handbook of the Vulnerable Plaque. 1st Edition. Waksman R, Serruys PW, editors -London: CRC Press;2004. - 48 p. ISBN 978-0-203-48989-5

15. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology. 2006;6(10):772–83. DOI: 10.1038/nri1937

16. Hu FB. Obesity epidemiology. - Oxford: Oxford Univ. Press;2008. - 498 p. ISBN 978-0-19-531291-1

17. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase- associated lipocalin and homologous proteins in rat and mouse. Biochimica et Biophysica Acta. 2000;1482(1–2):272–83. DOI: 10.1016/S0167-4838(00)00152-7

18. Yan L, Borregaard N, Kjeldsen L, Moses MA. The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity Is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinase-associated Lipocalin (NGAL). Journal of Biological Chemistry. 2001;276(40):37258–65. DOI: 10.1074/jbc.M106089200

19. Zhang Y, Foncea R, Deis JA, Guo H, Bernlohr DA, Chen X. Lipocalin 2 Expression and Secretion Is Highly Regulated by Metabolic Stress, Cytokines, and Nutrients in Adipocytes. PLoS ONE. 2014;9(5):e96997. DOI: 10.1371/journal.pone.0096997

20. Lindberg S, Pedersen SH, Mogelvang R, Jensen JS, Flyvbjerg A, Galatius S et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Journal of the American College of Cardiology. 2012;60(4):339–45. DOI: 10.1016/j.jacc.2012.04.017

21. Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D. Association of Neutrophil Gelatinase-Associated Lipocalin With the Severity of Coronary Artery Disease. The American Journal of Cardiology. 2009;104(7):917–20. DOI: 10.1016/j.amjcard.2009.05.023

22. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. European Journal of Endocrinology. 2008;158(2):203–7. DOI: 10.1530/EJE-07-0633

23. Sahinarslan A, Kocaman SA, Bas D, Akyel A, Ercin U, Zengin O et al. Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease: Coronary Artery Disease. 2011;22(5):333–8. DOI: 10.1097/MCA.0b013e3283472a71

24. Niaz S, Latif J, Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pakistan Journal of Medical Sciences. 2019;35(3):641–6. DOI: 10.12669/pjms.35.3.274

25. Calabro P, Cirillo P, Limongelli G, Maddaloni V, Riegler L, Palmieri R et al. Tissue Factor Is Induced by Resistin in Human Coronary Artery Endothelial Cells by the NF-ĸB-Dependent Pathway. Journal of Vascular Research. 2011;48(1):59–66. DOI: 10.1159/000318775

26. Park HK, Kwak MK, Kim HJ, Ahima RS. Linking resistin, inflammation, and cardiometabolic diseases. The Korean Journal of Internal Medicine. 2017;32(2):239–47. DOI: 10.3904/kjim.2016.229

27. Vaughan DE. PAI-1 and atherothrombosis. Journal of Thrombosis and Haemostasis. 2005;3(8):1879–83. DOI: 10.1111/j.1538-7836.2005.01420.x

28. Badran M, Gozal D. PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea? International Journal of Molecular Sciences. 2022;23(10):5516. DOI: 10.3390/ijms23105516

29. Golukhova E.Z., Grigoryan M.V., Ryabinina M.N., Bulaeva N.I. Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention. Rational Pharmacotherapy in Cardiology. 2016;12(5):528–35. DOI: 10.20996/1819-6446-2016-12-5-528-535

30. Parsson H, Holmberg A, Siegbahn A, Bergqvist D. Activation of Coagulation and Fibrinolytic Systems in Patients with CLI is not Normalized after Surgical Revascularisation. European Journal of Vascular and Endovascular Surgery. 2004;27(2):186–92. DOI: 10.1016/j.ejvs.2003.10.015

31. Dragunov D.O., Sokolova A.V., Arutyunov G.P., Mitrokhin V.M., Kamkin A.G., Latyshev T.V. Correlations of IL-18 and IL-6 with sodium consumption in patients with arterial hypertension and diabetes mellitus. Kardiologiia. 2017;17(S1):355–9. DOI: 10.18087/cardio.2389

32. Markova T.N., Mishchenko N.K., Petina D.V. Adipocytokines: modern definition, classification and physiological role. Problems of Endocrinology. 2022;68(1):73–80. DOI: 10.14341/probl12805

33. Wang Y, Meng R, Liu G, Cao C, Chen F, Jin K et al. Intracranial atherosclerotic disease. Neurobiology of Disease. 2019;124:118–32. DOI: 10.1016/j.nbd.2018.11.008

34. Su J-H, Luo M-Y, Liang N-, Gong S-X, Chen W, Huang W-Q et al. Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases. Frontiers in Pharmacology. 2021;12:745061. DOI: 10.3389/fphar.2021.745061

35. Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P et al. Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL Study. Journal of the American Heart Association. 2013;2(1):e003103. DOI: 10.1161/JAHA.112.003103

36. Wainstein MV, Mossmann M, Araujo GN, Goncalves SC, Gravina GL, Sangalli M et al. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. Diabetology & Metabolic Syndrome. 2017;9(1):67. DOI: 10.1186/s13098-017-0266-5

37. Moriya J. Critical roles of inflammation in atherosclerosis. Journal of Cardiology. 2019;73(1):22–7. DOI: 10.1016/j.jjcc.2018.05.010